These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

125 related items for PubMed ID: 21518617

  • 21. Safety and immunogenicity of the novel seasonal preservative- and adjuvant-free influenza vaccine: Blind, randomized, and placebo-controlled trial.
    Sarsenbayeva G, Volgin Y, Kassenov M, Issagulov T, Bogdanov N, Sansyzbay A, Abitay R, Nurpeisova A, Sagymbay A, Koshemetov Z, Stukova M, Buzitskaya Z, Кulmagambetov I, Karabayeva D, Davlyatshin T, Khairullin B.
    J Med Virol; 2018 Jan; 90(1):41-49. PubMed ID: 28842994
    [Abstract] [Full Text] [Related]

  • 22. Intradermally-administered influenza virus vaccine is safe and immunogenic in healthy adults 18-64 years of age.
    Gorse GJ, Falsey AR, Fling JA, Poling TL, Strout CB, Tsang PH.
    Vaccine; 2013 May 01; 31(19):2358-65. PubMed ID: 23499604
    [Abstract] [Full Text] [Related]

  • 23. Comparison of immunogenicity and reactogenicity of split versus subunit influenza vaccine in Korean children aged 6-35 months.
    Kim YK, Eun BW, Kim NH, Kang EK, Lee BS, Kim DH, Lim JS.
    Scand J Infect Dis; 2013 Jun 01; 45(6):460-8. PubMed ID: 23294036
    [Abstract] [Full Text] [Related]

  • 24. Immunization with trivalent inactivated influenza vaccine in partially immunized toddlers.
    Englund JA, Walter EB, Gbadebo A, Monto AS, Zhu Y, Neuzil KM.
    Pediatrics; 2006 Sep 01; 118(3):e579-85. PubMed ID: 16950949
    [Abstract] [Full Text] [Related]

  • 25. A 2013/2014 northern hemisphere season surface antigen inactivated trivalent influenza vaccine--Assessing the immunogenicity and safety in an open label, uncontrolled study.
    Roggelin L, Vinnemeier CD, Meyer S, Witte K, Marx L, Theeß W, Burchard GD, Rolling T, Cramer JP.
    Hum Vaccin Immunother; 2015 Sep 01; 11(10):2370-5. PubMed ID: 26114800
    [Abstract] [Full Text] [Related]

  • 26. Long-lasting immunogenicity of a virosomal vaccine in older children and young adults with type I diabetes mellitus.
    Zuccotti GV, Scaramuzza A, Riboni S, Mameli C, Pariani E, Tanzi E, Zanetti A, Radaelli G.
    Vaccine; 2009 Aug 27; 27(39):5357-62. PubMed ID: 19607951
    [Abstract] [Full Text] [Related]

  • 27. Comparison between a conventional subunit vaccine and the MF59-adjuvanted subunit influenza vaccine in the elderly: an evaluation of the safety, tolerability and immunogenicity.
    Sindoni D, La Fauci V, Squeri R, Cannavò G, Bacilieri S, Panatto D, Gasparini R, Amicizia D.
    J Prev Med Hyg; 2009 Jun 27; 50(2):121-6. PubMed ID: 20099444
    [Abstract] [Full Text] [Related]

  • 28. Cross-protection against homologous drift variants of influenza A and B after vaccination with split vaccine.
    Heckler R, Baillot A, Engelmann H, Neumeier E, Windorfer A.
    Intervirology; 2007 Jun 27; 50(1):58-62. PubMed ID: 17164559
    [Abstract] [Full Text] [Related]

  • 29. Response to a monovalent 2009 influenza A (H1N1) vaccine.
    Greenberg ME, Lai MH, Hartel GF, Wichems CH, Gittleson C, Bennet J, Dawson G, Hu W, Leggio C, Washington D, Basser RL.
    N Engl J Med; 2009 Dec 17; 361(25):2405-13. PubMed ID: 19745216
    [Abstract] [Full Text] [Related]

  • 30. Intanza(®) 15 mcg intradermal influenza vaccine elicits cross-reactive antibody responses against heterologous A(H3N2) influenza viruses.
    Ansaldi F, Canepa P, Ceravolo A, Valle L, de Florentiis D, Oomen R, Vogel FR, Denis M, Samson SI, Icardi G.
    Vaccine; 2012 Apr 16; 30(18):2908-13. PubMed ID: 22342501
    [Abstract] [Full Text] [Related]

  • 31. Safety and immunogenicity of 3 seasonal trivalent influenza vaccines in the Chinese military.
    Gao D, Yang H, Deng B, Yin G, Song W, Zhang H, Li Y.
    Hum Vaccin Immunother; 2016 Oct 02; 12(10):2634-2639. PubMed ID: 27348250
    [Abstract] [Full Text] [Related]

  • 32. Immunogenicity, reactogenicity, and safety of inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccine in healthy adults aged ≥18 years: a phase III, randomized trial.
    Tinoco JC, Pavia-Ruz N, Cruz-Valdez A, Aranza Doniz C, Chandrasekaran V, Dewé W, Liu A, Innis BL, Jain VK.
    Vaccine; 2014 Mar 14; 32(13):1480-7. PubMed ID: 24486352
    [Abstract] [Full Text] [Related]

  • 33. A clinical study to assess the immunogenicity and safety of a monovalent 2009 influenza A (H1N1) vaccine in an area with low-level epidemics of pandemic influenza.
    Kung HC, Huang KC, Kao TM, Lee YC, Chang FY, Wang NC, Liu YC, Lee WS, Liu HJ, Chen CI, Chen CH, Huang LM, Hsieh SM.
    Vaccine; 2010 Oct 21; 28(45):7337-43. PubMed ID: 20817013
    [Abstract] [Full Text] [Related]

  • 34. Antibody responses to trivalent influenza vaccine in Iranian adults infected with human immunodeficiency virus.
    Rasoolinejad M, Jafari S, Montazeri M, Mohseni M, Foroughi M, Moradmand Badie B, Saatian M, Marashi SM, Mokhtari Azad T.
    Acta Med Iran; 2013 Apr 06; 51(3):148-52. PubMed ID: 23605597
    [Abstract] [Full Text] [Related]

  • 35. Safety and efficacy of a novel microneedle device for dose sparing intradermal influenza vaccination in healthy adults.
    Van Damme P, Oosterhuis-Kafeja F, Van der Wielen M, Almagor Y, Sharon O, Levin Y.
    Vaccine; 2009 Jan 14; 27(3):454-9. PubMed ID: 19022318
    [Abstract] [Full Text] [Related]

  • 36. Immunogenicity and safety of intradermal influenza vaccine in children.
    Esposito S, Daleno C, Picciolli I, Tagliaferri L, Scala A, Prunotto G, Montinaro V, Galeone C, Principi N.
    Vaccine; 2011 Oct 13; 29(44):7606-10. PubMed ID: 21855592
    [Abstract] [Full Text] [Related]

  • 37. [Safety and immunogenicity of split vaccines of influenza viruses].
    Zhu CL, Fang HH, Zhu FC, Wang YQ, Wu XL, Xue FB, Shen YJ, Lian JZ.
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2004 Sep 13; 18(3):207-9. PubMed ID: 15640848
    [Abstract] [Full Text] [Related]

  • 38. Efficacy of the trivalent influenza vaccination in Thai patients with hemodialysis or kidney transplant compared with healthy volunteers.
    Krairittichai U, Chittaganpitch M.
    J Med Assoc Thai; 2013 Mar 13; 96 Suppl 3():S1-7. PubMed ID: 23682516
    [Abstract] [Full Text] [Related]

  • 39. Pre-vaccination immunity and immune responses to a cell culture-derived whole-virus H1N1 vaccine are similar to a seasonal influenza vaccine.
    Ehrlich HJ, Müller M, Kollaritsch H, Pinl F, Schmitt B, Zeitlinger M, Loew-Baselli A, Kreil TR, Kistner O, Portsmouth D, Fritsch S, Maritsch F, Aichinger G, Pavlova BG, Barrett PN.
    Vaccine; 2012 Jun 22; 30(30):4543-51. PubMed ID: 22475864
    [Abstract] [Full Text] [Related]

  • 40. A randomized clinical trial to identify the optimal antigen and MF59(®) adjuvant dose of a monovalent A/H1N1 pandemic influenza vaccine in healthy adult and elderly subjects.
    Hatz C, von Sonnenburg F, Casula D, Lattanzi M, Leroux-Roels G.
    Vaccine; 2012 May 14; 30(23):3470-7. PubMed ID: 22446638
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.